Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.

Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page
- Check3 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing the previous v3.5.3.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page footer now shows an updated site revision number (from v3.5.2 to v3.5.3), indicating a new release of the ClinicalTrials.gov interface without altering the study information presented.SummaryDifference0.0%

- Check38 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check53 days agoChange DetectedThe Publications section was updated to include the 2024 Blood article by Friedberg et al. on frontline brentuximab vedotin therapy for older HL patients ineligible for chemotherapy, and the Erratum for that Blood article was removed.SummaryDifference0.0%

- Check67 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page; this appears to be a maintenance/versioning update with no changes to study content.SummaryDifference0.0%

- Check74 days agoChange DetectedFooter now displays Revision: v3.4.3 instead of Revision: v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.